IBDEI1NJ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27638,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,27638,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,27639,0)
 ;;=D47.3^^132^1320^61
 ;;^UTILITY(U,$J,358.3,27639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27639,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,27639,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,27639,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,27640,0)
 ;;=C82.09^^132^1320^62
 ;;^UTILITY(U,$J,358.3,27640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27640,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,27640,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,27640,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,27641,0)
 ;;=C82.00^^132^1320^63
 ;;^UTILITY(U,$J,358.3,27641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27641,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,27641,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,27641,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,27642,0)
 ;;=C82.19^^132^1320^64
 ;;^UTILITY(U,$J,358.3,27642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27642,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,27642,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,27642,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,27643,0)
 ;;=C82.10^^132^1320^65
 ;;^UTILITY(U,$J,358.3,27643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27643,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,27643,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,27643,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,27644,0)
 ;;=C82.29^^132^1320^66
 ;;^UTILITY(U,$J,358.3,27644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27644,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,27644,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,27644,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,27645,0)
 ;;=C82.20^^132^1320^67
 ;;^UTILITY(U,$J,358.3,27645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27645,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,27645,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,27645,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,27646,0)
 ;;=C82.39^^132^1320^68
 ;;^UTILITY(U,$J,358.3,27646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27646,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,27646,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,27646,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,27647,0)
 ;;=C82.30^^132^1320^69
 ;;^UTILITY(U,$J,358.3,27647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27647,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,27647,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,27647,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,27648,0)
 ;;=C82.49^^132^1320^70
 ;;^UTILITY(U,$J,358.3,27648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27648,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,27648,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,27648,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,27649,0)
 ;;=C82.40^^132^1320^71
 ;;^UTILITY(U,$J,358.3,27649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27649,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,27649,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,27649,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,27650,0)
 ;;=C82.99^^132^1320^72
 ;;^UTILITY(U,$J,358.3,27650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27650,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,27650,1,4,0)
 ;;=4^C82.99
